Rabeprazole sodium

(S)-Rabeprazole is a partially reversible gastric proton pump inhibitor.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump

Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump

Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump

AGN-195183 (IRX-5183) is a potent and selective agonist of RARα ( K d =3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.In VitroAGN-195183 (IRX-5183: Compound 4) inhibits the growth of breast

AGN-195183 (IRX-5183) is a potent and selective agonist of RARα ( K d =3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.In VitroAGN-195183 (IRX-5183: Compound 4) inhibits the growth of breast

AGN-195183 (IRX-5183) is a potent and selective agonist of RARα ( K d =3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.In VitroAGN-195183 (IRX-5183: Compound 4) inhibits the growth of breast

AGN-195183 (IRX-5183) is a potent and selective agonist of RARα ( K d =3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.In VitroAGN-195183 (IRX-5183: Compound 4) inhibits the growth of breast

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM: little and NO potency for SGLT1/3/4/5/6. IC50 value: 2.8 nM Target: SGLT2 in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse

Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM: little and NO potency for SGLT1/3/4/5/6. IC50 value: 2.8 nM Target: SGLT2 in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse